The U.S. has cleared its first two Covid-19 treatment pills, and now comes another hurdle -- deciding who should get which one.
Meanwhile, Pfizer Inc.’s Paxlovid -- authorized earlier this week --showed stronger clinical trial data with President
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.